View Older Stories
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
Oppenheimer Downgrades AtriCure Inc. (ATRC) to Perform
-
AtriCure Inc. (ATRC) PT Lowered to $52 at Citizens: Durable Revenue Growth Expected
-
AtriCure (ATRC) Tops Q4 EPS by 16c, provides guidance
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
AtriCure (ATRC) Reiterated at Market Outperform by Citizens Ahead of Q4 Earnings
-
JPMorgan Downgrades AtriCure Inc. (ATRC) to Neutral
-
Piper Sandler on AtriCure Inc. (ATRC): 'BoxX-NoAF Should Drive the Stock Appreciably Higher'
-
AtriCure reports 15% revenue growth for 2025, projects $600-610M in 2026
-
AtriCure Inc. (ATRC) PT Raised to $64 at Canaccord Genuity
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
Citizens Reiterates AtriCure Inc. (ATRC) at Market Outperform After Q3 Beats
-
AtriCure (ATRC) Tops Q3 EPS by 10c ; Offers Guidance
-
AtriCure (ATRC) PT Raised to $45 at Needham
-
AtriCure Inc. (ATRC) PT Raised to $45 at Needham
-
Citizens JMP Reiterates Market Outperform Rating on AtriCure Inc. (ATRC)
-
AtriCure (ATRC) Tops Q2 EPS by 4c
-
AtriCure completes enrollment in 6,500-patient stroke prevention trial
-
AtriCure Inc. (ATRC) PT Lowered to $44 at Needham
-
Citizens JMP Reiterates Market Outperform Rating on AtriCure Inc. (ATRC)
-
AtriCure (ATRC) Tops Q1 EPS by 8c ; Offers Guidance
-
AtriCure (ATRC) Announces First Use of the AtriClip PRO-Mini Device
-
Citizens JMP Reiterates Market Outperform Rating on AtriCure Inc. (ATRC)
-
UBS Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
Piper Sandler Calls AtriCure Inc. (ATRC) an 'Underappreciated Story'
-
Oppenheimer Reiterates Outperform Rating on AtriCure Inc. (ATRC)
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
AtriCure Inc. (ATRC) PT Raised to $58 at BTIG
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
AtriCure Inc. (ATRC) PT Raised to $57 at BTIG
-
JMP Securities Reiterates Market Outperform Rating on AtriCure Inc. (ATRC)
-
AtriCure (ATRC) Misses Q4 EPS by 13c, provides guidance
-
JMP Securities Reiterates Market Outperform Rating on AtriCure Inc. (ATRC)
-
AtriCure Inc. (ATRC) PT Raised to $51 at Needham
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
AtriCure (ATRC) Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 202
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
AtriCure Inc. (ATRC) PT Raised to $53 at Canaccord Genuity
-
AtriCure (ATRC) Tops Q3 EPS by 2c, provides guidance
-
AtriCure (ATRC) Receives CE-Mark for the EnCompass Clamp
-
AtriCure (ATRC) Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation
-
AtriCure Inc. (ATRC) PT Lowered to $40 at Piper Sandler
-
AtriCure Inc. (ATRC) PT Lowered to $53 at BTIG
-
AtriCure (ATRC) Reports In-Line Q2 EPS, provides guidance
-
AtriCure (ATRC) Receives Regulatory Approval to Sell AtriClip Devices in China
-
AtriCure Inc. (ATRC) PT Lowered to $35 at UBS
-
AtriCure (ATRC) July 20, 25 and 35 calls active
-
AtriCure (ATRC) July 20, 25 and 35 calls active
-
Edwards Lifesciences (EW) said to mull takeover bid for AtriCure (ATRC) - source

